Zyus Life Sciences【ZYUS】銘柄情報

Zyus Life Sciences Corporation (ZYUS) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

0.495

( - )

買値

0.06

売値

0.50

出来高

0.00 日の範囲 0.00

0.395 52 週間の範囲 0.77

時価総額

39.859M

前日終値

0.495

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

$ 8,967

発行済株式数

80,522,813

配当利回り

PER

-1.1

1 株当たり利益 (EPS)

-0.45

歳入

465k

純利益

-33.74M

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2... ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2 clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada. 詳細を表示

セクター

Healthcare

業界

Pharmaceuticals

ウェブサイト

www.zyus.com

本社

Saskatoon, Canada

設立

2026

Zyus Life Sciences Corporation is listed in the Healthcare sector of the トロントベンチャー取引所 with ticker ZYUS. The last closing price for Zyus Life Sciences was $0.50. Over the last year, Zyus Life Sciences shares have traded in a share price range of $ 0.395 to $ 0.77.

Zyus Life Sciences currently has 80,522,813 shares in issue. The market capitalisation of Zyus Life Sciences is $39.86 million. Zyus Life Sciences has a price to earnings ratio (PE ratio) of -1.10.

ZYUS Life Sciences Announces LIFE Offering of a minimum of C$15 Million and maximum of C$16 Million of Units

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SASKATOON, Saskatchewan, Jan. 12, 2026 (GLOBE...

ZYUS Life Sciences Finalizing Site Initiation for Phase 2A Clinical Trial Advancing Novel Non-Opioid Pain Drug

Paving the way for evidence-based solutions in cancer pain management with its lead drug product, Trichomylin® softgel capsules ZYUS Life...

ZYUS Life Sciences Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent covering Trichomylin® Formulation and Announces Unit Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES ZYUS Life Sciences Corporation (the “Company”...

INSERTING and REPLACING ZYUS Life Sciences Corporation to Present at Sidoti Virtual Investor Conference May 8-9

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Insert as subheadline: NOT FOR DISTRIBUTION TO U.S...

ZYUS Life Sciences Corporation to Present at Sidoti Virtual Investor Conference May 8-9

ZYUS Life Sciences Corporation (“ZYUS” or the “Company”) (TSXV: ZYUS) is pleased to announce that Brent Zettl, President and CEO of ZYUS, will...

ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management

ZYUS Receives Patent from United States Patent and Trademark Office (“USPTO”) Supporting ZYUS’ Lead Drug Candidate ZYUS Life Sciences Corporation...

ZYUS Strengthens Expertise of Clinical Advisory Committee with the Appointment of Dr. Hance Clarke

Dr. Clarke Joins ZYUS’ Clinical Advisory Committee, Bringing Extensive Expertise in Healthcare and Pain Management ZYUS Life Sciences Corporation...

ZYUS Strengthens Leadership Team with Appointment of Vice President of Clinical Research

Scott Livingstone brings extensive healthcare expertise and strategic leadership to ZYUS’ experienced team ZYUS Life Sciences Corporation (the...

ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin® Softgel Capsules for Advanced Cancer Pain Management

Evaluating Efficacy, Safety, and Tolerability in Patients with Moderate to Severe Cancer-Related Pain ZYUS Life Sciences Corporation ("ZYUS" or...

ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels

Completion of Phase 1 and Supportive Preclinical Data Will Assist in Ongoing Phase 2 Clinical Development of ZYUS’ Lead Drug Product Candidate...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0.495	0.495	0.495	0	0	CS
4	0	0	0.495	0.495	0.495	0	0	CS
12	-0.075	-13.1578947368	0.57	0.63	0.395	2627	0.50792457	CS
26	-0.165	-25	0.66	0.7	0.395	4516	0.58261563	CS
52	-0.225	-31.25	0.72	0.77	0.395	5411	0.64380129	CS
156	-1.375	-73.5294117647	1.87	1.92	0.395	7752	0.88325099	CS
260	-2.005	-80.2	2.5	2.5	0.395	8005	0.92212518	CS

ZYUS - Frequently Asked Questions (FAQ)

What is the current Zyus Life Sciences Corporation share price?

The current share price of Zyus Life Sciences Corporation is $ 0.495

How many Zyus Life Sciences Corporation shares are in issue?

Zyus Life Sciences Corporation has 80,522,813 shares in issue

What is the market cap of Zyus Life Sciences Corporation?

The market capitalisation of Zyus Life Sciences Corporation is CAD 39.86M

What is the 1 year trading range for Zyus Life Sciences Corporation share price?

Zyus Life Sciences Corporation has traded in the range of $ 0.395 to $ 0.77 during the past year

What is the PE ratio of Zyus Life Sciences Corporation?

The price to earnings ratio of Zyus Life Sciences Corporation is -1.1

What is the cash to sales ratio of Zyus Life Sciences Corporation?

The cash to sales ratio of Zyus Life Sciences Corporation is 85.72

What is the registered address of Zyus Life Sciences Corporation?

The registered address for Zyus Life Sciences Corporation is Unit 204, Saskatoon, Saskatchewan, S7N 4L8

What is the Zyus Life Sciences Corporation website address?

The website address for Zyus Life Sciences Corporation is www.zyus.com

Which industry sector does Zyus Life Sciences Corporation operate in?

Zyus Life Sciences Corporation operates in the Pharmaceuticals sector

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Zyus Life Sciences Corporation (ZYUS)

Zyus Life Sciences Corporation (ZYUS) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

Zyus Life Sciences Corporation について

ZYUS 最新ニュース

ZYUS Life Sciences Announces LIFE Offering of a minimum of C$15 Million and maximum of C$16 Million of Units

ZYUS Life Sciences Finalizing Site Initiation for Phase 2A Clinical Trial Advancing Novel Non-Opioid Pain Drug

ZYUS Life Sciences Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent covering Trichomylin® Formulation and Announces Unit Offering

INSERTING and REPLACING ZYUS Life Sciences Corporation to Present at Sidoti Virtual Investor Conference May 8-9

ZYUS Life Sciences Corporation to Present at Sidoti Virtual Investor Conference May 8-9

ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management

ZYUS Strengthens Expertise of Clinical Advisory Committee with the Appointment of Dr. Hance Clarke

ZYUS Strengthens Leadership Team with Appointment of Vice President of Clinical Research

ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin® Softgel Capsules for Advanced Cancer Pain Management

ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels

ZYUS Life Sciences Announces LIFE Offering of a minimum of C$15 Million and maximum of C$16 Million of Units

ZYUS - Frequently Asked Questions (FAQ)

ZYUS 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Zyus Life Sciences Corporation (ZYUS)

Zyus Life Sciences Corporation (ZYUS) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

Zyus Life Sciences Corporation について

ZYUS 最新ニュース

ZYUS Life Sciences Announces LIFE Offering of a minimum of C$15 Million and maximum of C$16 Million of Units

ZYUS Life Sciences Finalizing Site Initiation for Phase 2A Clinical Trial Advancing Novel Non-Opioid Pain Drug

ZYUS Life Sciences Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent covering Trichomylin® Formulation and Announces Unit Offering

INSERTING and REPLACING ZYUS Life Sciences Corporation to Present at Sidoti Virtual Investor Conference May 8-9

ZYUS Life Sciences Corporation to Present at Sidoti Virtual Investor Conference May 8-9

ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management

ZYUS Strengthens Expertise of Clinical Advisory Committee with the Appointment of Dr. Hance Clarke

ZYUS Strengthens Leadership Team with Appointment of Vice President of Clinical Research

ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin® Softgel Capsules for Advanced Cancer Pain Management

ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels

ZYUS Life Sciences Announces LIFE Offering of a minimum of C$15 Million and maximum of C$16 Million of Units

ZYUS - Frequently Asked Questions (FAQ)

ZYUS 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する